This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Palatin Technologies (PTN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
by Zacks Equity Research
A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
by Zacks Equity Research
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -5.88% and 63.32%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -6.78% and 9.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -22.41% and 4.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -23.53% and 2.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of -3.17% and 9.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 35.82% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.63% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 0% and 6.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 16% and 7.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Swedish Orphan Biovitrum (BIOVF) Beats Q3 Earnings Estimates
by Zacks Equity Research
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
by Zacks Equity Research
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -50% and 7.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Berkeley Lights, Inc. (BLI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -3.23% and 1.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -5.88% and 6.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar?
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -33.33% and 78.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -35.61% and 0.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?